2021
Age‐Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011–2018
Rhee TG, Kumar M, Ross JS, Coll PP. Age‐Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011–2018. Journal Of The American Geriatrics Society 2021, 69: 1272-1282. PMID: 33598936, PMCID: PMC9869399, DOI: 10.1111/jgs.17038.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAspirinCardiovascular DiseasesCross-Sectional StudiesFemaleHeart Disease Risk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedNutrition SurveysPrevalencePrimary PreventionSecondary PreventionUnited StatesConceptsUse of aspirinStatin useAspirin useCardiovascular riskSecondary preventionMedication usePrimary preventionAge-related trajectoriesAge 50Prevention treatmentAngina/angina pectorisLow-dose aspirin dailyLong-term statin useOlder adultsDaily aspirin usePrimary prevention treatmentSecondary prevention treatmentSubsequent CVD eventsFirst cardiovascular eventCoronary heart diseaseAdults Aged 50Nutrition Examination SurveyCross-sectional studyHealth Interview SurveyNon-institutionalized adultsPhysician variation in the de‐adoption of ineffective statin and fibrate therapy
Everhart A, Desai NR, Dowd B, Herrin J, Higuera L, Jeffery MM, Jena AB, Ross JS, Shah ND, Smith LB, Karaca‐Mandic P. Physician variation in the de‐adoption of ineffective statin and fibrate therapy. Health Services Research 2021, 56: 919-931. PMID: 33569804, PMCID: PMC8522575, DOI: 10.1111/1475-6773.13630.Peer-Reviewed Original ResearchMeSH KeywordsAgedDiabetes Mellitus, Type 2Drug Therapy, CombinationDrug UtilizationFemaleFibric AcidsGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsHypolipidemic AgentsLongitudinal StudiesMaleMedicare Part CMiddle AgedPractice Guidelines as TopicPractice Patterns, Physicians'Risk FactorsUnited StatesConceptsMedicare Advantage patientsType 2 diabetic patientsACCORD lipid trialFibrate useAdvantage patientsCommercial patientsPhysician characteristicsLIPID trialFibrate therapyDiabetic patientsPhysician variationDiabetes careType 2 diabetes diagnosisContinuous insurance enrollmentPatient diabetes carePhysician random effectsGlucose-lowering drugsElectronic health record dataHealth record dataReal-world data assetConcurrent statinCardiovascular eventsStatin usersClinical evidenceManagement visits
2018
Weighing the Harms and Benefits of Using Statins for Primary Prevention: Raising the Risk Threshold.
Richman IB, Ross JS. Weighing the Harms and Benefits of Using Statins for Primary Prevention: Raising the Risk Threshold. Annals Of Internal Medicine 2018, 170: 62-63. PMID: 30508426, DOI: 10.7326/m18-3066.Commentaries, Editorials and Letters
2017
Medicare Formulary Changes After the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline
Dhruva SS, Desai NR, Karaca-Mandic P, Shah ND, Ross JS. Medicare Formulary Changes After the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline. Journal Of The American College Of Cardiology 2017, 69: 244-246. PMID: 28081832, DOI: 10.1016/j.jacc.2016.10.053.Peer-Reviewed Original ResearchMeSH KeywordsAmerican Heart AssociationCardiologyCardiovascular DiseasesCholesterolHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMedicarePractice Guidelines as TopicSocieties, MedicalUnited States
2016
Impact of Hospitalization for Acute Myocardial Infarction on Adherence to Statins Among Older Adults
Kronish IM, Ross JS, Zhao H, Muntner P. Impact of Hospitalization for Acute Myocardial Infarction on Adherence to Statins Among Older Adults. Circulation Cardiovascular Quality And Outcomes 2016, 9: 364-371. PMID: 27220368, PMCID: PMC4956547, DOI: 10.1161/circoutcomes.115.002418.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overDatabases, FactualDyslipidemiasFemaleHealth Knowledge, Attitudes, PracticeHospitalizationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMedicareMedication AdherenceMyocardial InfarctionRisk AssessmentRisk FactorsTherapeuticsTime FactorsUnited StatesConceptsAcute myocardial infarctionImpact of hospitalizationAMI hospitalizationMyocardial infarctionProportion of patientsPatients adherentStatin adherentNonadherent patientsAdherent patientsMedicare patientsHospitalizationAdministrative claimsStatinsMedicare beneficiariesPatientsPneumoniaSubsequent adherenceOlder adultsInfarctionRandom sampleAdherenceAdherentYearsProportionCohort
2013
The Case for Generic Statins: Not If They Don’t Work So Well—Reply
Green JB, Ross JS, Krumholz HM. The Case for Generic Statins: Not If They Don’t Work So Well—Reply. JAMA Internal Medicine 2013, 173: 1474-1474. PMID: 23939523, DOI: 10.1001/jamainternmed.2013.7781.Commentaries, Editorials and LettersDirect-to-Consumer Television Advertising: Time to Turn Off the Tube?
Ross JS, Kravitz RL. Direct-to-Consumer Television Advertising: Time to Turn Off the Tube? Journal Of General Internal Medicine 2013, 28: 862-864. PMID: 23539285, PMCID: PMC3682047, DOI: 10.1007/s11606-013-2424-2.Commentaries, Editorials and LettersAdvertisingCommunity ParticipationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMaleTelevisionWhen Choosing Statin Therapy: The Case for Generics
Green JB, Ross JS, Jackevicius CA, Shah ND, Krumholz HM. When Choosing Statin Therapy: The Case for Generics. JAMA Internal Medicine 2013, 173: 229-232. PMID: 23303273, DOI: 10.1001/jamainternmed.2013.1529.Commentaries, Editorials and LettersMeSH KeywordsCardiovascular DiseasesChoice BehaviorDrugs, GenericDyslipidemiasEvidence-Based MedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsTherapeutic Equivalency
2011
Generic Atorvastatin and Health Care Costs
Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM. Generic Atorvastatin and Health Care Costs. New England Journal Of Medicine 2011, 366: 201-204. PMID: 22149736, PMCID: PMC3319770, DOI: 10.1056/nejmp1113112.Peer-Reviewed Original ResearchMeSH KeywordsAtorvastatinCost SavingsDrug CostsDrug IndustryDrugs, GenericHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsPyrrolesUnited StatesUse of Fibrates in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of Fibrates in the United States and Canada. JAMA 2011, 305: 1217-1224. PMID: 21427374, PMCID: PMC3332101, DOI: 10.1001/jama.2011.353.Peer-Reviewed Original ResearchMeSH KeywordsCanadaCardiovascular DiseasesCohort StudiesCosts and Cost AnalysisDiabetes Mellitus, Type 2Drug CostsDrugs, GenericFenofibrateFibric AcidsHealth ExpendituresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMedical AuditPractice Patterns, Physicians'PrescriptionsUnited StatesConceptsUse of fibratesRole of fibratesObservational cohort studyIMS Health dataFenofibrate useCardiovascular riskCohort studyDiabetes (ACCORD) trialClinical benefitFibratesMonthsPrescriptionUnited StatesPatientsNegative resultsFenofibrateHealth dataCurrent useGeneric formulationPopulationStatinsTherapyTrials
2008
Use of Ezetimibe in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of Ezetimibe in the United States and Canada. New England Journal Of Medicine 2008, 358: 1819-1828. PMID: 18375999, DOI: 10.1056/nejmsa0801461.Peer-Reviewed Original ResearchMeSH KeywordsAnticholesteremic AgentsAzetidinesCanadaCholesterol, LDLCohort StudiesDrug UtilizationEzetimibeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaPractice Patterns, Physicians'United StatesConceptsLipid-lowering agentsLow-density lipoprotein cholesterolLipid-lowering guidelinesRatio of prescriptionsUse of ezetimibeTreatment of hyperlipidemiaStatin useCohort studyLipoprotein cholesterolSecondary preventionStatin prescriptionClinical outcomesPrescribing practicesEzetimibeIMS HealthUnited StatesPrescriptionMonthly numberFirst optionDistinct patterns